Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery - PubMed
3 hours ago
- #urothelial carcinoma
- #real-world outcomes
- #adjuvant immunotherapy
- Adjuvant nivolumab demonstrated improved disease-free survival and overall survival compared to observation alone after radical surgery.
- The study utilized a real-world, multicenter cohort of high-risk bladder and upper tract urothelial carcinoma patients.
- Secondary analyses showed similar oncological outcomes between adjuvant nivolumab and adjuvant chemotherapy.
- Benefits were consistent for muscle-invasive bladder cancer patients, but data for upper tract urothelial carcinoma were inconclusive.
- Findings require further confirmation due to potential residual confounding factors.